DUL Stock Overview
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Alnylam Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$139.20 |
52 Week High | US$195.40 |
52 Week Low | US$133.40 |
Beta | 0.39 |
1 Month Change | -6.83% |
3 Month Change | -19.07% |
1 Year Change | -20.58% |
3 Year Change | 23.01% |
5 Year Change | 71.81% |
Change since IPO | 2,740.82% |
Recent News & Updates
Recent updates
Shareholder Returns
DUL | DE Biotechs | DE Market | |
---|---|---|---|
7D | 3.3% | 3.3% | 1.6% |
1Y | -20.6% | 35.8% | 6.4% |
Return vs Industry: DUL underperformed the German Biotechs industry which returned 35.8% over the past year.
Return vs Market: DUL underperformed the German Market which returned 6.4% over the past year.
Price Volatility
DUL volatility | |
---|---|
DUL Average Weekly Movement | 5.7% |
Biotechs Industry Average Movement | 5.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DUL's share price has been volatile over the past 3 months.
Volatility Over Time: DUL's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 2,100 | Yvonne Greenstreet | https://www.alnylam.com |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.
Alnylam Pharmaceuticals, Inc. Fundamentals Summary
DUL fundamental statistics | |
---|---|
Market cap | €17.68b |
Earnings (TTM) | -€406.48m |
Revenue (TTM) | €1.69b |
10.5x
P/S Ratio-43.5x
P/E RatioIs DUL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DUL income statement (TTM) | |
---|---|
Revenue | US$1.83b |
Cost of Revenue | US$310.41m |
Gross Profit | US$1.52b |
Other Expenses | US$1.96b |
Earnings | -US$440.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.50 |
Gross Margin | 83.02% |
Net Profit Margin | -24.08% |
Debt/Equity Ratio | -1,086.8% |
How did DUL perform over the long term?
See historical performance and comparison